Annals of Vascular Surgery
Volume 21, Issue 2 , Pages 149-154 , March 2007

Comparison of Retavase and Urokinase for Management of Spontaneous Subclavian Vein Thrombosis

References 

  1. Adams JT, McEvoy RK, DeWeese JA. Primary deep venous thrombosis of upper extremity. Arch Surg. 1965;91:29–41
  2. Tilney NL, Griffiths HJG, Edwards EA. Natural history of major venous thrombosis of the upper extremity. Arch Surg. 1970;101:792–796
  3. Adams JT, DeWeese JA. “Effort” thrombosis of the axillary and subclavian veins. J Trauma. 1971;11:923–930
  4. Gloviczki P, Kazmier FJ, Hollier LH. Axillary-subclavian venous occlusion: the morbidity of a non lethal disease. J Vasc Surg. 1986;4:333–337
  5. Steed DL, Teodori MF, Peitzman AB, McAuley CE, Kapoor WN, Webster MW. Streptokinase in the treatment of subclavian vein thrombosis. J Vasc Surg. 1986;4:28–32
  6. Kunkel JM, Machleder HI. Treatment of Paget-Schroetter syndrome: a staged, multidisciplinary approach. Arch Surg. 1989;124:1153–1158
  7. Smalling RW. Molecular biology of plasminogen activators: what are the clinical implications of drug design?. Am J Cardiol. 1996;78(Suppl 12A):2–7
  8. Brieger D, Topol EJ. Molecular biology and genetic engineering of plasminogen activators. In: Califf RM, editor. Continuing education series: thrombolytic therapy. New standards of care: part 1: the science of plasminogen activators. Am J Cardiol. 1996;16–22
  9. Machleder HI. Evaluation of a new treatment strategy for Paget-Schroetter syndrome: spontaneous thrombosis of the axillary-subclavian vein. J Vasc Surg. 1993;17:305–315
  10. Machleder HI. Thrombolytic therapy and surgery for primary axillosubclavian vein thrombosis: current approach. Semin Vasc Surg. 1996;9:46–49
  11. Hughes ESR. Venous obstruction in the upper extremity (Paget-Schroetter's syndrome): a review of 320 cases. International Abstract of Surgery. 1949;88:89–127
  12. Urschel HC, Razzuk MA. Improved management of the Paget-Schroetter syndrome secondary to thoracic outlet compression. Ann Thorac Surg. 1991;52:1217–1221
  13. Azakie A, McElhinney DB, Thompson RW, Raven RB, Messina LM, Stoney RJ. Surgical management of subclavian-vein effort thrombosis as a result of thoracic outlet compression. J Vasc Surg. 1998;28:777–786
  14. Adelman MA, Stone DH, Riles TS, Lamparello PJ, Giangola G, Rosen RJ. A multidisciplinary approach to the treatment of Paget-Schroetter syndrome. Ann Vasc Surg. 1997;11:149–154
  15. Kreienberg PB, Chang BB, Darling RC, et al. Long-term results in patients treated with thrombolysis, thoracic inlet decompression, and subclavian vein stenting for Paget-Schroetter syndrome. J Vasc Surg. 2001;33(2 Suppl):S100–S105
  16. Feugier P, Aleksic I, Salari R, et al. Long-term results of venous revascularization for Paget-Schroetter syndrome in athletes. Ann Vasc Surg. 2001;15:212–218
  17. Lee JT, Karwowski JK, Harris EJ, et al. Long-term thrombotic recurrence after nonoperative management of Paget-Schroetter syndrome. J Vasc Surg. 2006;43:1236–1243
  18. Ouriel K. Urokinase and the US Food and Drug Administration. J Vasc Surg. 1999;30(5):957–958
  19. Brieger D, Topol EJ. Molecular biology and genetic engineering of plasminogen activators. In: Califf RM, editor. Continuing education series: thrombolytic therapy. New standards of care: part 1: the science of plasminogen activators. Am J Cardiol. 1996;16–22

 Presented at the 24th Annual Meeting of the Southern California Vascular Surgery Society, Temecula, California, May 5-7, 2006.

PII: S0890-5096(07)00077-5

doi: 10.1016/j.avsg.2006.10.016

Annals of Vascular Surgery
Volume 21, Issue 2 , Pages 149-154 , March 2007

Article Tools

* Image Usage & Resolution